Showing results (61-70 of 194) with videos related to
Sort By:
Pageof 20
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive TreatmentNicole C Ammerman, Eric L Nuermberger, Andrew Owen, et al.Antimicrobial Agents and Chemotherapy|July 28, 2010
Clinical evaluation of a dried blood spot assay for atazanavirTrevor Van Schooneveld, Susan Swindells, Sarah R Nelson, et al.Journal of Neuroscience Methods|April 28, 2023
A novel 4-cell in-vitro blood-brain barrier model and its characterization by confocal microscopy and TEER measurementJohid R Malik, Courtney V Fletcher, Anthony T Podany, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 21, 2021
Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic optionsShetty Ravi Dyavar, Rahul Singh, Rohini Emani, et al.The Journal of Antimicrobial Chemotherapy|July 24, 2019
Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in miceShetty Ravi Dyavar, Nagsen Gautam, Anthony T Podany, et al.Journal of Neuroimmunology|May 5, 2005
Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjectsAnuja Ghorpade, Yury Persidsky, Susan Swindells, et al.AIDS Research and Human Retroviruses|February 17, 2015
HIV-Infected Patient Knowledge, Attitudes, and Beliefs Regarding the Affordable Care ActIrina Rozin, Harlan Sayles, Matthew J Anderson, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2019
Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical TrialsSachiko Miyahara, Ritesh Ramchandani, Soyeon Kim, et al.HIV Clinical Trials|April 19, 2011
Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysisSusan Swindells, Hongyu Jiang, A Lisa Mukherjee, et al.Pageof 20